Table 2.
European LeukaemiaNet criteria for hydroxycarbamide intolerance and resistance in patients with polycythemia vera
| 1. Need for phlebotomy to keep hematocrit < 45% after 3 months of at least 2 g/day of hydroxyurea, OR |
| 2. Uncontrolled myeloproliferation (i.e., platelet count > 400 × 109/L and WBC count > 10 × 109/L) after 3 months of at least 2 g/day of hydroxyurea, OR |
| 3. Failure to reduce massivea splenomegaly by > 50% as measured by palpation OR failure to completely relieve symptoms related to splenomegaly after 3 months of at least 2 g/day of hydroxyurea, OR |
| 4. Absolute neutrophil count < 1.0 × 109/L OR platelet count < 100 × 109/L OR hemoglobin < 10 g/dL at the lowest dose of hydroxyurea required to achieve a completeb or partialc clinicohematologic response, OR |
| 5. Presence of leg ulcers or other unacceptable hydroxyurea-related nonhematologic toxicities, such as mucocutaneous manifestations, GI symptoms, pneumonitis, or fever at any dose of hydroxyurea |
WBC, white blood cell; GI, gastrointestinal.
a
Organ extending by > 10 cm from the costal margin.
b
Complete response is defined as hematocrit less than 45% without phlebotomy, platelet count < 400 × 109/L, WBC count < 10 × 109/L, and no disease-related symptoms.
c
Partial response is defined as hematocrit less than 45% without phlebotomy or response in three or more of the other criteria.